Cagrilintide shows solid weight loss results in clinical trials, with higher doses driving stronger outcomes. In phase 2 data, top-end dosing reached ~10.8% bodyweight loss over 26 weeks, and when paired with semaglutide (CagriSema), results pushed to ~20% over 68 weeks, outperforming either compound alone. The effect is clearly dose-dependent, with higher ranges delivering more noticeable fat loss.
On the downside, side effects are mostly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, especially during dose increases. These are typically mild to moderate and temporary, and much easier to manage with slow titration. Some users may also experience mild injection-site irritation like redness or slight discomfort, but overall tolerability lines up with other appetite-regulating peptides when protocols are followed properly.